SEARCH

SEARCH BY CITATION

References

  • 1
    Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension. 2003;42:12061252.
  • 2
    Fields LE, Burt VL, Cutler JA, et al. The burden of adult hypertension in the United States 1999 to 2000: a rising tide. Hypertension. 2004;44:398404.
  • 3
    Ong KL, Cheung BM, Man YB, et al. Prevalence, awareness, treatment, and control of hypertension among United States adults 1999–2004. Hypertension. 2007;49:6975.
  • 4
    Blood Pressure Lowering Treatment Trialists' Collaboration. Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trials. Lancet. 2003;362:15271535.
  • 5
    Staessen JA, Wang J-G, Thijs L. Cardiovascular prevention and blood pressure reduction: a quantitative overview updated until 1 March 2003. J Hypertens. 2003;21:10551076.
  • 6
    Staessen JA, Li Y, Thijs L, et al. Blood pressure reduction and cardiovascular prevention: an update including the 2003–2004 secondary prevention trials. Hypertens Res. 2005;28:385407.
  • 7
    European Society of Hypertension-European Society of Cardiology Guidelines Committee. 2003 European Society of Hypertension-European Society of Cardiology guidelines for the management of arterial hypertension. J Hypertens. 2003;21:10111053.
  • 8
    Prospective Studies Collaboration. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet. 2002;360:19031913.
  • 9
    Burnier M, Brunner HR. Angiotensin II receptor antagonists. Lancet. 2000;355:637645.
  • 10
    Salerno CM, Demopoulos L, Mukherjee R, et al. Combination angiotensin receptor blocker/hydrochlorothiazide as initial therapy in the treatment of patients with severe hypertension. J Clin Hypertens (Greenwich). 2004;6:614620.
  • 11
    Lacourcière Y, Poirier L, Hebert D, et al. Antihypertensive efficacy and tolerability of two fixed-dose combinations of valsartan and hydrochlorothiazide compared with valsartan monotherapy in patients with stage 2 or 3 systolic hypertension: an 8-week, randomized, double-blind, parallel group trial. Clin Ther. 2005;27:10131021.
  • 12
    Sachse A, Verboom CN, Jäger B. Efficacy of eprosartan in combination with HCTZ in patients with essential hypertension. J Hum Hypertens. 2002;16:169176.
  • 13
    Pool J, Oparil S, Hedner T, et al. Dose-responsive antihypertensive efficacy of valsartan, a new angiotensin II-receptor blocker. Clin Ther. 1998;20:11061114.
  • 14
    Giles TD, Robinson TD. Effects of olmesartan medoxomil on systolic blood pressure and pulse pressure in the management of hypertension. Am J Hypertens. 2004;17:690695.
  • 15
    Leonardi-Bee J, Bath PM, Bousser MG, et al, on behalf of the Dipyridamole in Stroke Collaboration (DISC). Dipyridamole for preventing recurrent ischemic stroke and other vascular events: a meta-analysis of individual patient data from randomized controlled trials. Stroke. 2005;36:162168.
  • 16
    Lièvre M, Gueyffier F, Ekbom T, et al, for the INDANA Steering Committee. Efficacy of diuretics and beta-blockers in diabetic hypertensive patients: results from a meta-analysis. Diabetes Care. 2000;23(suppl 2):B65B71.
  • 17
    Pocock SJ, McCormack V, Gueyffier F, et al. A score for predicting risk of death from cardiovascular disease in adults with raised blood pressure, based on individual patient data from randomized controlled trials. BMJ. 2001;323:7581.
  • 18
    Gueyffier F, Boissel JP, Pocock S, et al. Identification of risk factors in hypertensive patients: contribution of randomized controlled trials through an individual patient database. Circulation. 1999;100:e88e94.
  • 19
    Whitehead A. Meta-Analysis of Controlled Clinical Trials. Chichester, England: John Wiley & Sons; 2003.
  • 20
    Thompson SG. Meta-analysis of clinical trials. In: ArmitageP, ColtonT, eds. Encyclopedia of Biostatistics. Chichester, England: John Wiley & Sons; 2005.
  • 21
    Pool JL, Glazer R, Chiang Y-T, et al. Dose-response efficacy of valsartan, a new angiotensin II receptor blocker. J Hum Hypertens. 1999;13:275281.
  • 22
    Oparil S, Dyke S, Harris F, et al. The efficacy and safety of valsartan compared with placebo in the treatment of patients with essential hypertension. Clin Ther. 1996;18:797810.
  • 23
    Holwerda NJ, Fogari R, Angeli P, et al. Valsartan, a new angiotensin II antagonist for the treatment of essential hypertension: efficacy and safety compared with placebo and enalapril. J Hypertens. 1996;14:11471151.
  • 24
    Benz JR, Black HR, Graff A, et al. Valsartan and hydrochlorothiazide in patients with essential hypertension: a multiple dose, double-blind, placebo controlled trial comparing combination therapy with monotherapy. J Hum Hypertens. 1998;12:861866.
  • 25
    Bremner AD, Baur M, Oddou-Stock P, et al. Valsartan: long-term efficacy and tolerability compared to lisinopril in elderly patients with essential hypertension. Clin Exp Hypertens. 1997;19:12631285.
  • 26
    Hall J, Marbury T, Gray J, et al. Long term safety, tolerability and efficacy of valsartan: results from one and two year trials. J Clin Res. 1998;1:147159.
  • 27
    Dickstein K, Kjekshus J, and the OPTIMAAL Steering Committee, for the OPTIMAAL Study Group. Effects of losartan and captopril on mortality and morbidity in high-risk patients after acute myocardial infarction: the OPTIMAAL randomised trial. Lancet. 2002;360 : 752760.
  • 28
    Pitt B, Poole-Wilson PA, Segal R, et al, on behalf of the ELITE II Investigators. Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial—the Losartan Heart Failure Survival Study ELITE II. Lancet. 2000;355:15821587.
  • 29
    Pfeffer MA, McMurray JJV, Velazquez EJ, et al, for the Valsartan in Acute Myocardial Infarction Trial Investigators. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med. 2003;349:18931906.
  • 30
    Julius S, Kjeldsen SE, Weber M, et al, for the VALUE trial group. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet. 2004;363:20222031.
  • 31
    Viberti G, Wheeldon NM, for the MicroAlbuminuria Reduction With VALsartan (MARVAL) Study Investigators. Microalbuminuria reduction with valsartan in patients with type 2 diabetes mellitus: a blood pressure-independent effect. Circulation. 2002;106:672678.
  • 32
    Mimran A, Weir MR. Angiotensin-receptor blockers and diuretics: advantages of combination. Blood Press. 2005;14:611.
  • 33
    Payne KA, Esmonde-White S. Observational studies of antihypertensive medication use and compliance: is drug choice a factor in treatment adherence? Curr Hypertens Rep. 2000;2:515524.
  • 34
    Caro JJ, Speckman JL, Salas M, et al. Effect of initial drug choice on persistence with antihypertensive therapy: the importance of actual practice data. CMAJ. 1999;160:4146.
  • 35
    Weir MR, Ferdinand KC, Flack JM, et al, for the AADVANCE Investigators. A noninferiority comparison of valsartan/hydrochlorothiazide combination versus amlodipine in black hypertensives. Hypertension. 2005;46:508513.